Incyte (NASDAQ: INCY) had its target price upped by Lazard Capital Markets from $25.00 to $27.00 in a research note issued to investors on Friday. The firm currently has a buy rating on the stock.

Shares of Incyte traded up 0.38% during mid-day trading on Friday, hitting $23.48. Incyte has a one year low of $15.43 and a one year high of $26.30. The stock’s 50-day moving average is currently $20.20. The company’s market cap is $3.144 billion.

Several other analysts have also recently commented on the stock. Analysts at Zacks reiterated a neutral rating on shares of Incyte in a research note to investors on Monday, February 18th. They now have a $23.00 price target on the stock. Separately, analysts at Barclays Capital raised their price target on shares of Incyte from $19.00 to $21.00 in a research note to investors on Friday, February 15th. They now have an equal weight rating on the stock. Finally, analysts at Jefferies Group cut their EPS estimates on shares of Incyte in a research note on Friday. They now have a buy rating and a $36.00 price target on the stock.

Thirteen investment analysts have rated the stock with a buy rating, three have issued a hold rating, and one has assigned a sell rating to the stock. The company has an average rating of overweight and a consensus price target of $25.23.

Incyte Corporation (Incyte) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.